Tuberculosis Treatment Optimization Study

Overview

This Phase II trial evaluates novel TB treatment regimens that could reduce treatment duration from 6 months to 4 months while maintaining or improving cure rates. The study focuses on optimizing drug combinations and dosing strategies.

Objectives

• Compare efficacy of 4-month vs 6-month regimens
• Assess treatment adherence and completion rates
• Evaluate safety and tolerability

Eligibility Criteria

Adults aged 18-65 with newly diagnosed drug-susceptible pulmonary tuberculosis